Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsSecurities - TradableShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Cash & Equivalents: 2022-2025

Historic Cash & Equivalents for Praxis Precision Medicines (PRAX) over the last 4 years, with Sep 2025 value amounting to $149.5 million.

  • Praxis Precision Medicines' Cash & Equivalents fell 11.34% to $149.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.5 million, marking a year-over-year decrease of 11.34%. This contributed to the annual value of $215.4 million for FY2024, which is 164.91% up from last year.
  • As of Q3 2025, Praxis Precision Medicines' Cash & Equivalents stood at $149.5 million, which was down 5.01% from $157.4 million recorded in Q2 2025.
  • In the past 5 years, Praxis Precision Medicines' Cash & Equivalents ranged from a high of $215.4 million in Q4 2024 and a low of $56.0 million during Q2 2022.
  • Moreover, its 3-year median value for Cash & Equivalents was $149.5 million (2025), whereas its average is $140.1 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first spiked by 164.91% in 2024, then decreased by 11.34% in 2025.
  • Over the past 4 years, Praxis Precision Medicines' Cash & Equivalents (Quarterly) stood at $61.6 million in 2022, then surged by 31.95% to $81.3 million in 2023, then surged by 164.91% to $215.4 million in 2024, then dropped by 11.34% to $149.5 million in 2025.
  • Its Cash & Equivalents was $149.5 million in Q3 2025, compared to $157.4 million in Q2 2025 and $165.6 million in Q1 2025.